The UK’s National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use of Genedrive’s CYP2C19 genotyping to guide clopidogrel treatment in patients who have suffered an Ischaemic Stroke (IS) or Transient Ischaemic Attack (TIA). NICE specifically recommends the Genedrive® CYP2C19-ID test as the preferred point-of-care testing solution.
Genedrive plc’s CYP2C19-ID test, which uses a non-invasive cheek swab, quickly identifies six genetic variants of the CYP2C19 gene. This information helps clinicians optimize treatment plans for stroke patients.
The NICE committee’s decision was based on a systematic review of clinical and economic impacts. They concluded that CYP2C19 genetic testing is both beneficial for patients with certain genetic variants and cost-effective compared to not testing.
With this recommendation and existing UKCA certification, Genedrive plc is now poised to commercialise its product in the UK and select Middle Eastern countries.
“We are delighted with this final guidance from NICE recommending implementation of CYP2C19 genotype-guided use of Clopidogrel in IS and TIA patients in the NHS to reduce risk of recurrent strokes, and recommendation of our CYP2C19 ID-kit as the point-of-care interventional platform of choice,” said James Cheek, CEO of genedrive plc.
“This represents a key milestone in our commercialisation plans for the product, and further solidifies our business strategy of leading provision of cost-effective solutions for pharmacogenetics in time critical emergency healthcare situations. We are proud to be at the forefront of the emergence of near-patient genetic testing in emergency healthcare to facilitate optimal personalised therapeutic choices and ultimately improve patient outcomes.”